A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPIn study)

Trial Profile

A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPIn study)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Secukinumab (Primary) ; Betamethasone; Calcipotriol
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms STEPIn study
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 09 May 2017 Planned number of patients changed from 205 to 196.
    • 09 May 2017 Planned End Date changed from 1 Feb 2022 to 19 Apr 2022.
    • 09 May 2017 Planned primary completion date changed from 1 Feb 2022 to 19 Apr 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top